CSIMarket Company Name, Ticker, Competitors, else..
 
Eyepoint Pharmaceuticals Inc   (EYPT)
Other Ticker:  
 
 
Price: $10.1700 $1.34 15.176%
Day's High: $10.3 Week Perf: 19.93 %
Day's Low: $ 8.82 30 Day Perf: 11.76 %
Volume (M): 1,071 52 Wk High: $ 30.99
Volume (M$): $ 10,893 52 Wk Avg: $14.53
Open: $8.92 52 Wk Low: $5.67



 Market Capitalization (Millions $) 390
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 43
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 58
 Capital Exp. (TTM) (Millions $) 3

Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc is a specialty biopharmaceutical company that focuses on developing innovative and sustained-release therapeutics for treating various eye diseases. The company's primary goal is to improve patient outcomes and provide more convenient treatment options for ophthalmic conditions. Eyepoint employs advanced technology to develop unique drug delivery systems that can achieve long-lasting therapeutic effects with a single dose. Their product portfolio includes treatments for conditions such as macular edema, posterior uveitis, and other retinal diseases. Eyepoint Pharmaceuticals aims to transform the treatment landscape for eye diseases and enhance the quality of life for patients.


   Company Address: 480 Pleasant Street Watertown 2472 MA
   Company Phone Number: 926-5000   Stock Exchange / Ticker: NASDAQ EYPT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4): A Strategic Leap Towards Talent and Growth,

Published Mon, Sep 16 2024 11:01 AM UTC

Navigating Challenges, Generating Opportunities: EyePoint Pharmaceuticalsn Strategic Inducement Awards
EyePoint Pharmaceuticals Inc., a prominent player in the market for retinal disease therapeutics, is making the headlines with its recent strategic decision to grant non-statutory stock options to new employees. By utilizing NASDAQ Listing Rule 5635(c)(4), the company h...
Stock Market Announcement

EyePoint Pharmaceuticals Expands Team With Inducement Awards, Bolstering Growth Potential,

Published Fri, Aug 16 2024 11:00 AM UTC

EyePoint Pharmaceuticals Grants Inducement Awards to New Employees Outside of Long-Term Incentive Plan
EyePoint Pharmaceuticals, a leading developer and marketer of therapeutics for serious retinal diseases, has recently announced the granting of non-statutory stock options to new employees. This move comes as part of the company's commitment to attracting top talent and...
Shares

EyePoint Pharmaceuticals Continues to Attract Top Talent with Inducement Grants

Published Tue, Jul 16 2024 11:00 AM UTC


EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a leading company in developing therapeutics for serious retinal diseases, has once again made headlines with its recent announcement of granting non-statutory stock options to new employees as inducement awards. This decision, made outside of the company's existing Long-Term Incentive Plan, is in accordance with NASDAQ Lis...
Clinical Study

EyePoint Pharmaceuticals Announces R&D Day to Showcase Advances in Retinal Disease Therapeutics

Published Tue, Jun 18 2024 11:00 AM UTC

EyePoint Pharmaceuticals, a leading pharmaceutical company dedicated to enhancing the lives of patients with serious retinal diseases, has announced the hosting of an exclusive Research and Development (R&D) Day. The event, scheduled for June 26, 2024, aims to provide insights into the company's ongoing research efforts and showcase advancements in their therapeutic solution...
Management Announcement

EyePoint Pharmaceuticals Grants Inducement Awards Amidst Financial Struggles

Published Mon, Jun 17 2024 11:00 AM UTC


By

EyePoint Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of therapies for serious retinal diseases, recently announced the grant of non-statutory stock options under NASDAQ Listing Rule 5635(c)(4) to new employees. This move comes as the company grapples with significant financial challenges, includ...






Eyepoint Pharmaceuticals Inc's Segments

  Eyepoint Pharmaceuticals Inc Outlook

On March 7 2024 the Eyepoint Pharmaceuticals Inc provided following guidance

EyePoint Pharmaceuticals Inc. has released their financial results for the fourth quarter and full year of 2023, along with highlighting recent corporate developments. One of the most significant updates includes the announcement of positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (AMD). This study successfully met all primary and secondary endpoints, marking a significant milestone for the company.

Following these promising results, EyePoint Pharmaceuticals Inc. anticipates initiating the first Phase 3 clinical trial for EYP-1901 in the second half of 2024. This advancement in the development of EYP-1901 highlights the compan...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com